ArticleCureus2025
Serum Mitsugumin-53 Level as a Diagnostic Marker in Patients With Acute Coronary Syndrome: A Case-Control Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe high incidence of acute coronary syndrome (ACS) warrants the search for new cardiac biomarkers. Mitsugumin-53 (MG-53) is a myokine involved in cell membrane repair and essential for the function and survival of cardiomyocytes. Therefore, the study assessed the utility of serum MG-53 levels in ACS diagnosis and prognosis.
methodWe enrolled 120 ACS patients as cases and 40 healthy controls as per the inclusion and exclusion criteria in this case-control study. The demographics, present and past history, and physical characteristics were recorded. The chemistry analyzer analyzed routine blood investigations. Serum MG-53 and heart-type fatty acid binding protein (H-FABP as a myocardial injury marker) levels were measured using enzyme-linked immunosorbent assay (ELISA) kits. The Statistical Package for the Social Sciences (SPSS) program (version 26.0, IBM Corp., Armonk, NY) was used for statistical analysis, such as independent t-test, chi-squared test, Pearson's and Spearman's correlation, receiver operating characteristic (ROC) curve, and univariate and multivariate logistic regression. A p-value <0.05 was considered statistically significant.
resultsPatients with ACS as cases had higher serum MG-53 and H-FABP levels than controls (p < 0.001). Serum MG-53 level was significantly positively correlated with serum troponin-I (correlation coefficient (r) = 0.520, p < 0.001), creatine kinase-MB (r = 0.298, p = 0.001), and H-FABP (r = 0.792, p < 0.001). The ROC curve showed that the serum MG-53 level had an area under the curve of 0.846 (95% CI: 0.781-0.911, p < 0.001) and sensitivity and specificity of 70%. Multivariate logistic regression depicted that the serum MG-53 level (OR = 1.113, 95% CI: 1.028-1.297, p < 0.001) was significantly associated with ACS risk after adjusting for age, weight, systolic blood pressure, random blood glucose, and serum total cholesterol levels. Multivariate linear regression showed a significant positive association between serum MG-53 and H-FABP levels in patients with different ACS severity and vessel diseases (p < 0.001). Conclusion: The serum MG-53 level may be considered one of the diagnostic markers in ACS patients. However, further studies need to confirm our findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.